ArticleBMC immunology2026
The correlation between the systemic immune-inflammation index and relapse and metastasis in cervical squamous cell carcinoma patients over 50 years and older.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to confirm the association of systemic immune-inflammation index (SII) with relapse and metastasis of cervical squamous cell carcinoma (CSCC) in patients over 50 years and older.
methodsThis retrospective study included 470 patients aged 50 years and older with CSCC who were treated at the Second Affiliated Hospital of Dalian Medical University between January 2020 and January 2023. The patients were divided into two groups according to median SII: high SII (n = 235) and low SII (n = 235). Univariate and multivariate logistic regression analysis, subgroup analysis, and receiver operating characteristic curve (ROC) analysis were used to explore the association of SII with relapse and metastasis.
resultsThe total population was 470, of which 161 (34%) relapsed and 133 metastasized (28.3%). Compared with low SII, high SII group had higher probability of relapse and metastasis (P < 0.05). Multivariate logistic regression analysis showed that, after adjusting for all confounding factors, each additional standard deviation in SII increased the risk of relapse by 28.5%, and the risk of relapse was 1.568 times higher for high SII than for low SII (P < 0.05). In addition, each additional unit in log
conclusionHigher levels of SII are significantly associated with a higher risk of relapse and metastasis, indicating that SII may have important clinical value in the prognosis assessment of CSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.